Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug’s long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists’ prescribing decisions in the treatment of this disorder.
Popularity: unranked [?]
Related posts:
- For Bipolar Depression, Surveyed Experts Indicate That Current And Emerging Therapies Have No Advantage Over Seroquel In Decreasing The Syptoms
- New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder
- Astrazeneca Submits Seroquel XR™ In Europe For The Treatment Of Major Depressive Disorder
- FDA Approves Cymbalta® For Maintenance Treatment Of Major Depressive Disorder
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder
Comments
No Responses to “Current And Emerging Drugs Continue To Struggle For Patient Share In The Treatment Of Major Depressive Disorder”